Who is sponsoring NCT03988998?

NCT03988998 is sponsored by Guangxi Medical University.

What drugs are being tested in NCT03988998?

Interventions in NCT03988998: Radiofrequency ablation with radiotherapy, Radiofrequency ablation alone.

What condition does NCT03988998 study?

NCT03988998 studies Hepatocellular Carcinoma.

Is NCT03988998 still recruiting?

NCT03988998 is currently status unknown. Last updated 18 January 2022.

Last reviewed 2022-01-18 · How we verify

NCT03988998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma

Status unknown Phase 3 Last updated 18 January 2022

What this trial tests

Phase 3 trial testing Radiofrequency ablation with radiotherapy in Hepatocellular Carcinoma in 100 participants. Status unknown.

Timeline

10 January 2022

Primary endpoint
31 December 2022

31 January 2023

Quick facts

Lead sponsor	Guangxi Medical University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	10 January 2022
Primary completion	31 December 2022
Estimated completion	31 January 2023

Drugs / interventions tested

Radiofrequency ablation with radiotherapy — full drug profile →
Radiofrequency ablation alone — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Guangxi Medical University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Radiofrequency ablation (RFA) and hepatic resection are main treatments for early stage hepatocellular carcinoma. Many randomized controlled trials found these two treatments have similar short term overall survival. However, hepatic resection is associated with higher long-term overall survival. These results reveal that tumor recurrence rate after RFA is higher than that after hepatic resection. And minimal residual tumor may exist after RFA. Radiotherapy after RFA may be effective to prevent early tumor recurrence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiofrequency ablation: mechanisms and clinical applications.
Wu J, Zhou Z, Huang Y, Deng X, et al · · 2024 · cited 24× · PMID 39359691 · DOI 10.1002/mco2.746

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Guangxi Medical University trials

Trials by the same sponsor.

NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT06851104 — A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence · Phase 2 · terminated
NCT05711823 — Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC · Phase 3 · unknown
NCT05910970 — Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation · Phase 3 · unknown
NCT06161272 — Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03988998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangxi Medical University
Last refreshed: 18 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing